Barclays analysts checked in on each of their stocks and adjusted their ratings and price targets. The results? A bump-up for Merck and a ding for Pfizer.

After initial doubts, some analysts now like Takeda's chances of pulling off a deal for embattled Shire.

Just five months after Allergan’s CEO said the company wouldn’t break up, it’s reportedly weighing options for its women’s health unit.

Don't lose all hope for a Pfizer consumer health sale. Procter & Gamble is still at the negotiating table, CNBC’s David Faber reports.

Takeda hasn’t even approached Shire’s board with a buyout offer yet, but competing bidders could jump in quickly, thanks to U.K. takeover rules.

While Shire’s shareholders Wednesday celebrated a possible Takeda bid, the Japanese drugmaker’s investors ran for the exits.

Shire has long been a popular buyout target, and it’s the latest to catch Takeda’s eye.

Turns out GSK didn't walk away from Pfizer's consumer health deal just because of its asking price. The U.K. drug giant had another buyout in mind.